Studies of ICIs combined with ADCs are an especially promising avenue, as preclinical data suggest that drugs like T-DXd may augment T-cell activity, upregulate PD-L1 expression, increase the number of tumor-infiltrating CD8 + T cells, and enhance the expression of PD-L1 and MHC class I molecules on the surface of tumor cells. The gene discussed is CD8A; the disease is neoplasm.